Outcome measures for technique survival reported in peritoneal dialysis: A systematic review.

Peritoneal dialysis systematic review technique survival transfer to haemodialysis

Journal

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
ISSN: 1718-4304
Titre abrégé: Perit Dial Int
Pays: United States
ID NLM: 8904033

Informations de publication

Date de publication:
05 2022
Historique:
pubmed: 23 4 2021
medline: 6 5 2022
entrez: 22 4 2021
Statut: ppublish

Résumé

Peritoneal dialysis (PD) technique survival is an important outcome for patients, caregivers and health professionals, however, the definition and measures used for technique survival vary. We aimed to assess the scope and consistency of definitions and measures used for technique survival in studies of patients receiving PD. MEDLINE, EMBASE and CENTRAL databases were searched for randomised controlled studies (RCTs) conducted in patients receiving PD reporting technique survival as an outcome between database inception and December 2019. The definition and measures used were extracted and independently assessed by two reviewers. We included 25 RCTs with a total of 3645 participants (41-371 per trial) and follow up ranging from 6 weeks to 4 years. Terminology used included 'technique survival' (10 studies), 'transfer to haemodialysis (HD)' (8 studies) and 'technique failure' (7 studies) with 17 different definitions. In seven studies, it was unclear whether the definition included transfer to HD, death or transplantation and eight studies reported 'transfer to HD' without further definition regarding duration or other events. Of those remaining, five studies included death in their definition of a technique event, whereas death was censored in the other five. The duration of HD necessary to qualify as an event was reported in only four (16%) studies. Of the 14 studies reporting causes of an event, all used a different list of causes. There is substantial heterogeneity in how PD technique survival is defined and measured, likely contributing to considerable variability in reported rates. Standardised measures for reporting technique survival in PD studies are required to improve comparability.

Sections du résumé

BACKGROUND
Peritoneal dialysis (PD) technique survival is an important outcome for patients, caregivers and health professionals, however, the definition and measures used for technique survival vary. We aimed to assess the scope and consistency of definitions and measures used for technique survival in studies of patients receiving PD.
METHOD
MEDLINE, EMBASE and CENTRAL databases were searched for randomised controlled studies (RCTs) conducted in patients receiving PD reporting technique survival as an outcome between database inception and December 2019. The definition and measures used were extracted and independently assessed by two reviewers.
RESULTS
We included 25 RCTs with a total of 3645 participants (41-371 per trial) and follow up ranging from 6 weeks to 4 years. Terminology used included 'technique survival' (10 studies), 'transfer to haemodialysis (HD)' (8 studies) and 'technique failure' (7 studies) with 17 different definitions. In seven studies, it was unclear whether the definition included transfer to HD, death or transplantation and eight studies reported 'transfer to HD' without further definition regarding duration or other events. Of those remaining, five studies included death in their definition of a technique event, whereas death was censored in the other five. The duration of HD necessary to qualify as an event was reported in only four (16%) studies. Of the 14 studies reporting causes of an event, all used a different list of causes.
CONCLUSION
There is substantial heterogeneity in how PD technique survival is defined and measured, likely contributing to considerable variability in reported rates. Standardised measures for reporting technique survival in PD studies are required to improve comparability.

Identifiants

pubmed: 33882725
doi: 10.1177/0896860821989874
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

279-287

Auteurs

Emma Elphick (E)

School of Medicine, Keele University, Newcastle, UK.

Matthew Holmes (M)

School of Medicine, Keele University, Newcastle, UK.

Matthew Tabinor (M)

School of Medicine, Keele University, Newcastle, UK.

Yeoungjee Cho (Y)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.
Australasian Kidney Studies Network, The University of Queensland, Brisbane, Australia.
Translational Research Institute, Brisbane, Australia.

Thu Nguyen (T)

Department of Renal Medicine, Auckland City Hospital, Auckland, New Zealand.

Tess Harris (T)

Polycystic Kidney Disease International, Geneva, Switzerland.
Polycystic Kidney Disease Charity, London, UK.

Angela Yee Moon Wang (AYM)

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.

Arsh K Jain (AK)

Department of Medicine, Western University, London, Ontario, Canada.

Daniela Ponce (D)

Botucatu School of Medicine, University of Sao Paulo State-UNESP, Brazil.

Josephine Sf Chow (JS)

Clinical Innovation and Business Unit, South Western Sydney Local Health District, Sydney, Australia.
Faculty of Nursing, University of Sydney, Sydney, Australia.
UNSW Faculty of Medicine, University of New South Wales, Sydney, Australia.
School of Health Science, University of Tasmania, Hobart, Australia.

Annie-Claire Nadeau-Fredette (AC)

Maisonneuve-Rosemont Research Centre and Hospital, Montreal, Canada.

Adrian Liew (A)

The Kidney and Transplant Practice, Mount Elizabeth Novena Hospital, Singapore.

Neil Boudville (N)

Medical School, University of Western Australia, Crawley, Australia.

Allison Tong (A)

Sydney School of Public Health, University of Sydney and Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia.

David W Johnson (DW)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.
Australasian Kidney Studies Network, The University of Queensland, Brisbane, Australia.
Translational Research Institute, Brisbane, Australia.

Simon J Davies (SJ)

School of Medicine, Keele University, Newcastle, UK.

Jeffrey Perl (J)

Division of Nephrology, St Michael's Hospital and the Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Ontario, Canada.

Karine E Manera (KE)

Sydney School of Public Health, University of Sydney and Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia.

Mark Lambie (M)

School of Medicine, Keele University, Newcastle, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH